Pharmacodynamic Comparisons for single loading doses of prasugrel (30 mg) and clopidogrel (600 mg) in healthy Korean volunteers

Circulation Journal

Volumn 77, Issue 5, 2013, Pages 1253-1259

  Kim, Moo Hyun ^a   Zhang, Hong Zhe ^a   Jung, Dong Keun ^a,b  

^a Dong A University College of Medicine   (South Korea)

^b Dong A University   (South Korea)

Author keywords

Clopidogrel; Light transmission aggregometry; Multiple electrode platelet aggregometry; Prasugrel; Verifynow

Indexed keywords

CLOPIDOGREL; PRASUGREL;

ADULT; ARTICLE; CROSSOVER PROCEDURE; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; RISK ASSESSMENT; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; ANALYSIS OF VARIANCE; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; HUMANS; MALE; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; REPUBLIC OF KOREA; THIOPHENES; TICLOPIDINE; TIME FACTORS; YOUNG ADULT;

EID: 84876750493     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0783     Document Type: Article

References (30)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
2. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-STsegment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.
3. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 4582 patients with acute myocardial infarction: Randomized placebo controlled trial. Lancet 2005; 366: 1607-1621.
4. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
5. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for immediate Clopidogrel Effect) Trial. Circulation 2005; 112: 2946-2950.
6. Montelascot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segments elevation acute coronary Syndro es. J Am Coll Cardiol 2006; 48: 931-938.
7. Nishio R, Shinke T, Otake H, Sawada T, Haraguchi Y, Shinohara M, et al. Effect of cytochrome P450 polymorphism on target lesion outcome after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 2012; 76: 2348-2355.
8. Park KW, Kim HS. Options to overcome clopidogrel response variability. Circ J 2012; 76: 287-292.
9. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
10. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834.
11. Wiviott SD, Braunwald E, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, et al. Randomized comparison of prasugrel (CS-747, LY 640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366-3373.
12. Antman EM, Wiviott SD, Murphy SA, Murphy SA, Voitk J, Hasin Y, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51: 2028-2033.
13. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
14. Payne CD, Li YG, Small DS, Ernest CS 2nd, Farid NA, Jakubowski JA, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007; 50: 555-562.
15. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
16. Jakubowski JA, Matsushima N, Asai F, Naganuma H, Brandt JT, Hirota T, et al. A multiple dose study of prasugrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007; 63: 421-430.
17. Small DS, Kothare P, Yuen E, Lachno DR, Li YG, Winters KJ, et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol 2010; 66: 127-135.
18. Harrison P, Frelinger AL III, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007; 120: 323-336.
19. Yu LH, Kim MH, Zhang HZ, Park TH, Kim YD, Cha KS, et al. Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: Platelet responsiveness and clinical outcome. Korean Circ J 2012; 42: 382-389.
20. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
21. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010; 104: 279-286.
22. Small DS, Payne CD, Kothare P, Yuen E, Natanegara F, Loh MY, et al. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: An open-label trial. Clin Ther 2010; 32: 365-379.
23. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzylio W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
24. Jakubowski JA, Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 2006; 47: 377-384.
25. Varenhorst C, James S, Erlinge D, Braun OO, Brandt JT, Winters KJ, et al. Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009; 157: 562.e1-e9.
26. Yokoi H, Kimura T, Isshiki T, Ogawa H, Ikeda Y. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. Thromb Res 2012; 129: 623-628.
27. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66.e9-e16.
28. Norgard NB, Abu-fadel M. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manag 2009; 5: 873-882.
29. Small DS, Farid NA, Payne CD, Brandt JT, Jakubowski JA, Salazar DE, et al. Prasugrel 60 mg and clopidogrel 300 mg loading doses: A pharmacokinetic basis for the observed difference in platelet aggregation response. Am J Cardiol 2006; 98: 200M.
30. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: A novel thienopyridine antiplatelet agent: A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-374.